GlassScriptPhysician profile
Brant J Lutsi
NPI 1265608186
$8,228.30
in general payments reported to CMS, 2019-2025
34 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $152 · 2021: $162 · 2022: $530 · 2023: $1,195 · 2024: $1,875 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,413 · Education: $19.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,412.98 |
| Education | $19.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $1,144.87 | 2019 | |
| Abbvie INC. | $1,127.08 | 2019-2025 | |
| Janssen Biotech, INC. | $910.46 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $685.44 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $544.07 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $338.35 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Intercept Pharmaceuticals, INC. | $289.36 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $286.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $272.92 | 2022-2025 | Dupixent |
| Celgene Corporation | $261.47 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $232.12 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $221.15 | 2023-2025 | |
| Medtronic, INC. | $213.07 | 2024-2025 | Signia, Gi Genius |
| Lilly USA, LLC | $196.61 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $184.05 | 2019-2025 | Rebyota, Clenpiq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $183.67 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $177.69 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $115.61 | 2019-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $102.09 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $100.10 | 2021-2023 | |
| Biocon Biologics INC | $94.19 | 2023-2025 | Yesintek, Hulio |
| Merck Sharp & Dohme LLC | $87.86 | 2022-2024 | Dificid |
| Braintree Laboratories, INC. | $80.95 | 2019-2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $76.94 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $51.70 | 2019-2024 | |
| Vivus LLC | $34.98 | 2025 | Pancreaze |
| Evoke Pharma, INC. | $34.68 | 2022 | |
| Ucb, INC. | $34.64 | 2019 | |
| Shionogi INC | $32.31 | 2019-2020 | |
| Romark Laboratories, Lc | $27.78 | 2019 | |
| Mirum Pharmaceuticals, INC. | $23.69 | 2025 | Livmarli |
| Aimmune Therapeutics, INC. | $23.59 | 2024 | |
| Concordia Pharmaceuticals INC. | $21.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.64 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brant Lutsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.